Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 31 July 2026.
The UK Government led the round with a £20m investment to support upcoming rocket launches and development programmes.
"Britain’s impressive toolkit of scientific talent, world class facilities, and unique geography means we stand ready to lead the charge and to work together with our international partners as a key part of the new space revolution in Europe."
Ventura Capital led the Series E round, with participation from Aviva Ventures, Horizons Ventures, and the Gates Foundation, to advance clinical trials and commercialise breath tests.
"Testament to the power of Breath Biopsy is the continued strong support we continue to enjoy from our investors. The funds closed will enable us to progress our business to the next stage, advancing clinical trials and supporting the launch and commercialization of our pipeline of unique breath tests."
The Series D round was led by NEA and values the business at $2.1bn.
"This new investment will help us develop a new generation of AI-powered video experiences that are interactive, real-time, and personalized, offering possibilities we could have only imagined when we founded the company in 2017. I’m excited to bring these experiences to our over 60,000 customers, which range from the world’s largest brands to thousands of small businesses that use Synthesia to communicate internally and externally with unmatched engagement and efficiency,"
Novo Holdings, Glenview Capital and b2venture led the Series E round, which will fund commercial expansion in the US.
"Our commitment to delivering innovative solutions for acute care has never been stronger. This financing round provides the resources to solidify Quanta as the best-in-class solution across the care continuum, to significantly expand our commercial operations, while continuing to introduce enhancements that will strengthen our long-term competitive position."
The Series D round was backed by strategic investors including AstraZeneca, HAT SGR, Hitachi Ventures, and Leaps by Bayer.
"We have known Huma for several years and we’ve been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care."
